Co-Diagnostics, Inc. Q3 2024 Earnings Call Highlights

Co-Diagnostics, Inc. (NASDAQ: CODX) held its Q3 2024 earnings call on November 7, 2024, at 4:30 PM ET. The call was led by Andrew Benson, Head of Investor Relations, alongside CEO Dwight Egan and CFO Brian Brown. The company released its financial results for the third quarter, ending September 30, 2024, earlier the same day. A press release detailing these results is available on Co-Diagnostics' website.

During the call, management provided prepared remarks followed by a Q&A session with analysts. Co-Diagnostics highlighted its forthcoming Co-Dx PCR testing platform, which is currently under review by the U.S. FDA for regulatory approval and marketing authorization. This platform is not yet available for sale.

The company cautioned that forward-looking statements made during the call are subject to risks and uncertainties, with actual results potentially differing from these statements. Factors influencing these outcomes are detailed in the company's SEC filings. Co-Diagnostics also noted that they might discuss non-GAAP financial measures during the call.